Inhibition of intracellular tumour necrosis factor (TNF)-α and interleukin (IL)-6 production in human monocytes by iloprost

European Journal of Clinical Investigation

Volumn 33, Issue 11, 2003, Pages 1013-1017

  Czeslick, E G ^a   Simm, A ^a   Grond, S ^a   Silber, R E ^a   Sablotzki, A ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Flow cytometry; IL 6; Iloprost; Monocyte; TNF

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ILOPROST; INTERLEUKIN 6; PROSTACYCLIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; ILOPROST; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242721929     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01241.x     Document Type: Article

References (15)

1. Lehmann C, König JP, Dettmann J, Birnbaum J, Kox WJ. Effects of iloprost, a stable prostacyclin analog, on intestinal leucocyte adherence and microvascular blood flow in rat experimental endotoxemia. Crit Care Med 2001;29 (7):1412-6.
2. Grundmann HJ, Hahnle U, Hegenscheid B, Sahlmuller G, Bienzle U, Blitstein-Willinger E. Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis 1992;165:501-5.
3. Eisenhut T, Sinha B, Göttrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993;26:259-64.
4. Jörres A, Luttmann W, Scholz P, Thierauch K-H, Gahl GM, Topley N et al. Specific inhibition of tumour necrosis factor in endotoxin-stimulated mononuclear leukocytes by the prostacyclin analogue Iloprost. Clin Intensive Care 1994;5:296-302.
5. Hagiwara E, Abbasi F, Mor G, Ishigatsubo Y, Klinman DM. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-alpha in human peripheral blood. Cytokine 1995;7 (8):815-22.
6. Haskil S, Johnson C, Eiermann D, Becker S, Warren K. Adherence induces selective mRNA expression of monocyte mediators and protooncogenes. J Immunol 1988;140:1690-4.
7. ++ monocytes are a Major Source of TNF. J Immunol 2002;68 (7):3536-42.
8. West MA, Heagy W, Endotoxin tolerance: A review. Crit Care Med 2002;30 (1):64-73.
9. Vernon CM, Picker LJ. Identification of functional subsets by flow cytometry. Intracellular detection cytokine expression. Cytometry 1998;34:207-15.
10. Yaqoob P, Newsholme EA, Calder C. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cyokine 1999;11 (8):600-5.
11. Hildebrand M, Krause W, Fabian H, Koziol T, Neumayer HH. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance haemodialysis. Int J Pharmacol Res 1990;10 (5):285-92.
12. Hildebrand M, Krause W, Oberender HA, Zurdel-Dillinger S, Jung S, Bodenburg H. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease. Eicosanoids 1990;3 (3):145-8.
13. Hildebrand M. Pharmacokinetics and tolerability of oral iloprost in thrombangiitis obliterans patients. Eur J Clin Pharmacol 1997;53:51-6.
14. Jörres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 1997;9 (2):119-25.
15. Jörres A, Luttmann W, Scholz P, Thierauch K-H, Gahl GM, Topley N et al. Specific inhibition of tumour necrosis factor in endotoxin-stimulated mononuclear leukocytes by the prostacyclin analogue iloprost. Clin Intensive Care 1994;5:296-302.